Mouse pre-microRNA Expression Construct mir-200c
- Known as:
- Mouse pre-microRNA Expression Construct mir-200c
- Catalog number:
- mmir-200c-pa-1
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Sbi systeme bioscience
- Gene target:
- Mouse pre-microRNA Expression Construct mir-200c
Related genes to: Mouse pre-microRNA Expression Construct mir-200c
- Gene:
- MIR200C NIH gene
- Name:
- microRNA 200c
- Previous symbol:
- MIRN200C
- Synonyms:
- hsa-mir-200c
- Chromosome:
- 12p13.31
- Locus Type:
- RNA, micro
- Date approved:
- 2004-04-23
- Date modifiied:
- 2019-01-24
Related products to: Mouse pre-microRNA Expression Construct mir-200c
Related articles to: Mouse pre-microRNA Expression Construct mir-200c
- For thirty years, the five-year survival rate for oral squamous cell carcinoma (OSCC) has remained below 60%. One major limitation is the absence of delivery systems that can take advantage of the molecular weaknesses unique to OSCC. MicroRNAs (miRNAs) control tumor-suppressive and carcinogenic pathways post-transcriptionally, but their therapeutic application is hindered by endosomal sequestration, low cellular uptake and quick nuclease-mediated destruction. These obstacles are addressed by nanocarrier platforms, while translational evidence unique to OSCC is dispersed. - Source: PubMed
Publication date: 2026/09/21
Jaffer Hussain Shazia FathimaPathuthara Rishal MohammedMulla MushirMulla MunazAdil Abdul HabeebKarobari Mohmed Isaqali - Acute lymphoblastic leukemia (ALL) represents the most common malignancy diagnosed in children, accounting for approximately 25-30% of all pediatric cancers. Despite remarkable improvements in survival rates over recent decades, with cure rates exceeding 90% in developed countries, the diagnosis and monitoring of ALL continue to rely on invasive bone marrow aspiration and morphological assessment. MicroRNAs (miRNAs), small non-coding RNA molecules that regulate gene expression post-transcriptionally, have emerged as promising biomarkers for cancer diagnosis and prognosis due to their stability in biological fluids, tissue-specific expression patterns, and regulatory roles in oncogenesis. This comprehensive review systematically examines the current evidence regarding miRNA expression profiles in pediatric ALL, focusing on their diagnostic potential, prognostic value, and applicability as non-invasive biomarkers. Aberrant miRNA expression has been consistently demonstrated in pediatric ALL, with specific signatures distinguishing B-cell precursor ALL from T-cell ALL, identifying cytogenetic subtypes, and predicting treatment response. Circulating miRNAs, particularly those packaged within exosomes, offer non-invasive alternatives for minimal residual disease monitoring and early relapse detection. Machine learning approaches integrating multi-miRNA panels have achieved high diagnostic accuracy, with several miRNAs, including miR-128-3p, miR-181a, miR-196b, miR-200c, and miR-326, demonstrating significant clinical utility. MicroRNA profiling represents a transformative approach to pediatric ALL management, offering enhanced diagnostic precision, improved risk stratification, and non-invasive monitoring capabilities. While challenges remain in standardizing detection methodologies and establishing clinically validated thresholds, the integration of miRNA biomarkers into clinical practice holds substantial promise for personalized medicine in childhood leukemia. - Source: PubMed
Publication date: 2026/08/25
Abuhassan QamarAl-Khreisat Mutaz JamalYounis Shahad Mohammed DhiaaKubaev AzizShaymardanov OlimSalih Rasim MJaber Mohamed Adil - Immune checkpoint inhibitors (ICIs) have shown promise in cancer therapy by enhancing antitumor immune responses, but patient responses are variable, with some experiencing limited efficacy and others suffering from severe immune‑related adverse events (irAEs). Identifying predictive biomarkers for ICI efficacy and toxicity is required for optimizing patient selection and treatment outcomes. MicroRNAs (miRNAs), small non‑coding RNA molecules that regulate gene expression, have emerged as potential biomarkers due to their role in immune regulation and tumor biology. Studies have shown that miRNA profiles in tumor tissues and blood can predict ICI responses. Specific miRNAs, such as miR‑155, miR‑21 and miR‑146a, are associated with enhanced antitumor responses, whereas others, such as miR‑34a and miR‑200c, are linked to resistance by modulating immune evasion. Additionally, altered miRNA expression reflects immune activation or dysregulation, playing a role in irAEs. The present review discussed the potential of miRNAs as predictive biomarkers for ICI therapy, their challenges in clinical integration and their promise for improving ICI treatment precision and safety, although further research is required for clinical application. - Source: PubMed
Publication date: 2026/08/21
Wang XiDuan BaojunBai JunLiu Huitong - Cancer stem cells (CSCs) drive therapeutic resistance, metastasis, and tumor recurrence through reversible transitions among stem-like, differentiated, epithelial, and mesenchymal states, which are sustained by interconnected epigenetic mechanisms. To our knowledge, this is the first review to integrate curcumin-mediated regulation of DNA methylation, chromatin remodeling, and non-coding RNAs within a single CSC plasticity framework and to propose the concept of an "epigenetic collapse of CSC plasticity" as a mechanistic explanation for how curcumin may weaken stemness, state switching, and adaptive treatment resistance. Evidence was critically evaluated through structured searches of PubMed/MEDLINE, Scopus, Web of Science Core Collection, Google Scholar, and citation tracking, while direct curcumin-epigenetic evidence was distinguished from independent CSC evidence and inferential mechanistic links. Curcumin has been reported to modulate DNMT1 and locus-specific DNA methylation; regulate HDACs, p300/CBP, EZH2, H3K27me3, and BMI1; and alter selected microRNA, long non-coding RNA, and circular RNA pathways, with comparatively stronger evidence involving the miR-34 family, miR-200c, miR-21, H19, and circHN1. However, current evidence is constrained by the predominance of bulk cancer-cell models, heterogeneous formulations and exposure conditions, and the scarcity of epigenetic rescue experiments combined with rigorous functional CSC assays. By unifying previously fragmented epigenetic evidence, this review advances a new evidence-weighted model in which curcumin may suppress CSC persistence not through a single molecular target, but by destabilizing the multilayer epigenetic circuitry that enables plasticity. Curcumin should therefore be regarded as a context-dependent, multilayer epigenetic modulator rather than an established CSC-eradicating therapy, and its translational relevance requires validation in prospectively defined CSC models with pharmacologically justified delivery and exposure conditions. - Source: PubMed
Publication date: 2026/08/02
Rana Juie NahushkumarGhosh JayashriMumtaz Sohail - MicroRNAs (miRNAs or miRs) represent conserved non‑coding RNAs responsible for the regulation of gene expression in a post‑transcriptional manner. The dysregulation of miRNAs often leads to disease development and progress. In particular, miR‑200c is one of the miR‑200 family members, which is found deregulated in various pathologies and involved in the process of cancer progression through its participation in different molecular signaling pathways. Initially, miR‑200c was regarded as an essential factor in metastases formation. Nevertheless, following the increase in knowledge about cell death signaling pathways, it became clear that miR‑200c participates in various types of cell death such as apoptosis, autophagy and pyroptosis. The present narrative review primarily discusses the molecular mechanisms through which miR‑200c regulates apoptosis, pyroptosis and autophagy and explores its potential therapeutic value. - Source: PubMed
Publication date: 2026/07/31
Wang XiaonaDu HuaShi Yingxu